NDAORALTABLETPriority Review
Approved
Dec 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
16
Clinical Trials (5)
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
Started Oct 2021
61 enrolled
Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IV Prostate Cancer AJCC v8+2 more
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
Started Nov 2020
20 enrolled
Leiomyosarcoma
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
Started Apr 2020
13 enrolled
Metastatic Castration-resistant Prostate Cancer
Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma
Started Jan 2020
34 enrolled
Esophagus Cancer, AdenocarcinomaStomach Cancer, Adenocarcinoma
Rucaparib Maintenance Therapy in Advanced Cervical Cancer
Started Oct 2019
0Cervical Cancer
Loss of Exclusivity
LOE Date
Aug 17, 2035
115 months away
Patent Expiry
Aug 17, 2035
Exclusivity Expiry
Dec 17, 2028